- Home
- IEP vs SYRE Comparison
IEP vs SYRE Comparison
Compare IEP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEP | SYRE |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.5B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IEP | SYRE |
|---|---|---|
| Price | $7.41 | $75.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $85.08 |
| AVG Volume (30 Days) | ★ 1.0M | 837.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 24.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,658,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $13.93 |
| 52 Week High | $9.75 | $79.54 |
Technical Indicators
Market Signals| Indicator | IEP | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 55.43 |
| Support Level | $7.08 | $66.78 |
| Resistance Level | $8.25 | $76.15 |
| Average True Range (ATR) | 0.10 | 4.03 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 15.91 | 61.06 |
Price Performance
Historical ComparisonAbout IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.